SyntheticMR AB publishes information document regarding the rights issue

SyntheticMR AB has launched a rights issue of approximately SEK 32.8 million, resolved by its board on 17 December 2025 and approved at an extraordinary general meeting on 9 January 2026; the information document has been registered with the Swedish Financial Supervisory Authority and is available on the company website. Trading in subscription rights runs 20–29 January 2026, the subscription period is 20 January–3 February 2026, with the outcome expected to be published on 4 February 2026; Sedermera Corporate Finance, Foyen Advokatfirma and Nordic Issuing AB are engaged as advisers. The announcement is largely procedural and compliant with Prospectus Regulation requirements and includes cross-border distribution restrictions and standard forward‑looking disclaimers.

Analysis

Market structure: The SEK 32.8m rights issue is a classic small‑cap cash raise that mechanically increases free float and dilutes existing holders; winners are short‑term liquidity providers, new buyers of rights at a discount, and banks/agents collecting fees, while incumbent shareholders who don’t subscribe will see immediate %-ownership erosion. Expect modest downward pressure on SyntheticMR’s share price during 20–29 Jan subscription‑rights trading and potential increase in intraday liquidity; negligible systemic market impact beyond Nordic small‑cap medtech/software peers.

Risk assessment: Tail risks include a failed/undersubscribed issue forcing bridge financing or distressed M&A (low probability, high impact) and regulatory/reimbursement setbacks for SyntheticMR’s imaging software that would make the fundraising insufficient. Immediate (days) risk is market repricing around the rights window; short‑term (weeks) depends on subscription ratio announced ~4 Feb; long‑term (quarters) hinges on cash runway vs. burn and ability to convert trial customers into revenue.

Trade implications: Direct plays: favor buying tradable subscription rights if they trade >15–20% below theoretical ex‑rights price between 20–29 Jan, targeting a 1–3 week hold post‑allocation; conversely, consider a tactical short of SyntheticMR if the company market cap <SEK 328m (implying the raise >10% of cap), size 2–4% notional. Options: use short‑dated put spreads or buy call spreads around expiry to exploit elevated event volatility; rotate 1–2% portfolio weight from micro‑cap Nordic medtech/software into larger, cash‑generative peers.

Contrarian angle: Consensus will treat this as dilution pain — but if subscription is heavily supported by insiders or strategic investors, equity may re‑rate on reduced financing risk; the market may underprice that optionality. A mispriced opportunity exists buying rights/calls when market cap implied dilution >10% but subscription indications show >80% takeup — asymmetric upside with capped downside via spreads.

Key Decisions for Investors

• If SyntheticMR market cap is <SEK 328m (rights >10% of cap), establish a tactical 2–4% short position in the equity during 20–29 Jan, trim if allocation/subscribe ratio announced on 4 Feb shows >80% takeup.
• Monitor and consider buying subscription rights during 20–29 Jan if they trade >15% below the theoretical ex‑rights value; target a 15–30% quick gain and exit within 1–3 weeks after the 4 Feb outcome.
• If rights price implies >25% downside and options exist, buy calendar call spreads (near‑term to 2–3 months) sized 1–2% to capture re‑rating if the raise secures runway; alternatively buy put spreads to limit downside if you short.
• Reduce micro/small‑cap Nordic healthcare‑software exposure by 1–2% and reallocate into larger, cash‑positive sector peers (increase allocation to large Nordic medtech/healthcare IT by 1–2%) to lower financing risk concentration.
• Set hard stop/loss thresholds: cut any new long rights/call spread positions if subscription indications on 4 Feb show <60% takeup or if new guidance extends cash runway <6 months.